Hospital
Reed City Hospital Corporation
Reed City Hospital Corporation was paid $15.02M by Medicaid between Jan 2018 and Dec 2024, across 209 billing codes. Its largest line is 99284, emergency room visit (serious) — 21% of everything it billed.
33Billing provider infoREED CITY HOSPITAL CORPORATION
REED CITY, MI 49677
REED CITY, MI 49677
33aNPI1437259843assigned 09/25/2006
33bProvider typeCritical Access Hospital
28Total paid$15.02M
24GClaims394,432
24DCodes billed209
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Michigan
Rank by total paid#3 of 31
Median peer was paid$6.03M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official COX, MATTHEW controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 45,193 | $1.25M | |
| 2019 | 41,952 | $1.13M | |
| 2020 | 54,188 | $2.01M | |
| 2021 | 67,353 | $2.60M | |
| 2022 | 68,049 | $2.81M | |
| 2023 | 65,176 | $2.73M | |
| 2024incomplete | 52,521 | $2.48M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 12,792 | 12,066 | $3.10M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 15,067 | 14,338 | $2.38M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 6,929 | 6,475 | $2.29M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7.9% | 9,710 | 8,551 | $1.18M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 3.9% | 3,260 | 2,011 | $590K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.7% | 5,931 | 5,769 | $550K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 3,009 | 2,925 | $547K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.3% | 3,068 | 2,412 | $348K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.2% | 5,791 | 4,393 | $333K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.1% | 2,519 | 1,464 | $309K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.7% | 2,301 | 2,256 | $254K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 6,164 | 4,964 | $220K |
197 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 8,712 | $217K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 4,700 | $217K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 2,244 | $153K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,876 | $147K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 409 | $126K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,785 | $106K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,315 | $102K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,726 | $96K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,708 | $92K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,734 | $91K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 422 | $84K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 267 | $82K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,343 | $81K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 827 | $72K |
| 80061 | Lipid panel | <1% | 5,793 | $64K |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,634 | $62K |
| 80053 | Comprehensive metabolic panel | <1% | 24,208 | $56K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 369 | $49K |
| 76830 | Ultrasound, transvaginal | <1% | 610 | $48K |
| 80050 | General health panel | <1% | 1,505 | $41K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,583 | $40K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 1,150 | $39K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 64 | $39K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 23,217 | $36K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,348 | $32K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,274 | $31K |
| 96367 | <1% | 709 | $31K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 59 | $31K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 465 | $31K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 134 | $30K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,530 | $29K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,716 | $28K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,360 | $23K |
| 82947 | <1% | 2,466 | $22K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,125 | $20K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,098 | $19K |
| 96415 | <1% | 345 | $19K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 981 | $19K |
| Q3014 | Telehealth originating site facility fee | <1% | 887 | $18K |
| 86900 | <1% | 500 | $17K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 973 | $17K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 26 | $16K |
| 93975 | <1% | 92 | $15K | |
| 72100 | <1% | 367 | $14K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 734 | $14K |
| 71250 | <1% | 203 | $13K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 93 | $12K |
| 93971 | <1% | 172 | $11K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 666 | $10K |
| 96376 | <1% | 1,522 | $10K | |
| 82728 | <1% | 1,247 | $9K | |
| 73630 | <1% | 916 | $8K | |
| 94060 | <1% | 53 | $8K | |
| 85027 | <1% | 3,609 | $8K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,127 | $8K |
| 84439 | <1% | 1,925 | $7K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 99 | $7K |
| G0378 | Hospital observation service, per hour | <1% | 22 | $7K |
| 73130 | <1% | 943 | $7K | |
| 82607 | <1% | 955 | $7K | |
| 85610 | <1% | 3,572 | $7K | |
| 73030 | <1% | 405 | $7K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,674 | $6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 803 | $6K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 668 | $6K |
| 83880 | <1% | 1,492 | $6K | |
| 83735 | <1% | 5,906 | $6K | |
| 83550 | <1% | 1,242 | $6K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 159 | $6K |
| 97162 | <1% | 137 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,089 | $5K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 12 | $5K |
| 73562 | <1% | 293 | $4K | |
| 84702 | <1% | 749 | $4K | |
| 83540 | <1% | 1,254 | $4K | |
| 73610 | <1% | 637 | $4K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 229 | $4K |
| 76642 | <1% | 69 | $4K | |
| 82746 | <1% | 433 | $3K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $3K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 246 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,498 | $3K |
| 82570 | <1% | 1,021 | $3K | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 187 | $3K |
| 81001 | <1% | 11,049 | $3K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 37 | $3K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 38 | $3K |
| 72141 | <1% | 12 | $2K | |
| 87077 | <1% | 1,408 | $2K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 42 | $2K |
| 77336 | <1% | 31 | $2K | |
| 73110 | <1% | 236 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 211 | $2K |
| 83655 | <1% | 185 | $2K | |
| 82043 | <1% | 478 | $2K | |
| 86140 | <1% | 988 | $1K | |
| 76536 | <1% | 26 | $1K | |
| 74018 | <1% | 51 | $1K | |
| 81025 | <1% | 4,568 | $1K | |
| 87186 | <1% | 703 | $1K | |
| 85007 | <1% | 1,565 | $1K | |
| 0012A | <1% | 42 | $1K | |
| 84100 | <1% | 1,415 | $1K | |
| 82565 | <1% | 1,642 | $1K | |
| 83690 | <1% | 4,420 | $1K | |
| 71271 | <1% | 17 | $1K | |
| 76801 | <1% | 12 | $967.08 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 66 | $939.40 |
| 0011A | <1% | 41 | $938.65 | |
| 80074 | <1% | 38 | $847.65 | |
| 85652 | <1% | 913 | $846.72 | |
| 73502 | <1% | 54 | $768.88 | |
| 97161 | <1% | 21 | $679.85 | |
| 87070 | <1% | 193 | $675.22 | |
| 87205 | <1% | 747 | $628.21 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 12 | $615.65 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,774 | $568.79 |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 80 | $553.62 |
| 96417 | <1% | 20 | $533.93 | |
| 0002A | <1% | 17 | $521.13 | |
| 86780 | <1% | 53 | $520.96 | |
| 80076 | <1% | 101 | $502.54 | |
| 87081 | <1% | 1,229 | $351.74 | |
| 72040 | <1% | 12 | $335.68 | |
| 85730 | <1% | 511 | $286.08 | |
| 83605 | <1% | 3,321 | $272.95 | |
| 0001A | <1% | 15 | $239.25 | |
| 84146 | <1% | 16 | $214.50 | |
| 84484 | <1% | 4,945 | $207.29 | |
| 85379 | <1% | 766 | $182.15 | |
| 85055 | <1% | 14 | $143.19 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,848 | $142.67 |
| 87340 | <1% | 57 | $135.00 | |
| 82784 | <1% | 24 | $129.34 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 633 | $109.82 |
| 87040 | <1% | 365 | $103.56 | |
| 86850 | <1% | 419 | $80.90 | |
| 87808 | <1% | 54 | $73.74 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 13,789 | $64.47 |
| 73080 | <1% | 26 | $63.90 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,185 | $51.08 |
| 82077 | <1% | 645 | $49.03 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,474 | $44.24 |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 223 | $42.04 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 672 | $39.40 |
| 83615 | <1% | 15 | $34.64 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 429 | $34.24 |
| 84550 | <1% | 26 | $32.56 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,336 | $30.26 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,922 | $28.10 |
| J2704 | Injection, propofol, 10 mg | <1% | 930 | $25.91 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 415 | $19.19 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,464 | $15.37 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,985 | $11.99 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 72 | $11.87 |
| 84156 | <1% | 15 | $11.08 | |
| 87147 | <1% | 39 | $7.81 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,051 | $6.29 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 602 | $5.94 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 586 | $4.59 |
| A9270 | Non-covered item or service | <1% | 1,346 | $4.32 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,935 | $3.24 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,177 | $2.53 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,593 | $1.41 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 6,394 | $0.01 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 2,565 | $0.00 |
| 80143 | 0% | 52 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 386 | $0.00 |
| 90715 | 0% | 137 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 645 | $0.00 |
| 80179 | 0% | 55 | $0.00 | |
| 91300 | 0% | 32 | $0.00 | |
| 94729 | 0% | 14 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 13 | $0.00 |
| 82805 | 0% | 72 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 13 | $0.00 |
| 99152 | 0% | 40 | $0.00 | |
| 82010 | 0% | 14 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 12 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 12 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 275 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 724 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 555 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 877 | $0.00 |
| 12001 | 0% | 71 | $0.00 | |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 14 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 217 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 51 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 78 | $0.00 |
| 87503 | 0% | 30 | $0.00 | |
| 76377 | 0% | 37 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 29 | $0.00 |
| 87807 | 0% | 13 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 43 | $0.00 |
| A9573 | Injection, gadopiclenol, 1 ml | 0% | 110 | $0.00 |
| 91301 | 0% | 83 | $0.00 | |
| 12002 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOX, MATTHEW (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.